Granulox Haemoglobin Spray

Granulox® is an oxygenating spray for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, arterial leg ulcers, and mixed leg ulcers for the secondary healing of surgical wounds and pressure sores . It can also be used on healing of sloughy and infected wounds. When Granulox is sprayed on a wound, highly purified haemoglobin is released. This binds with oxygen from the environment and diffuses through the wound exudate, and the haemoglobin supplies the base of the wound topically with oxygen. The oxygen supply to the base of the wound supports wound healing and patient outcomes. A convenient spray application makes Granulox a portable and easy-to-use adjunct to standard of care wound treatment. Granulox can be applied when the wound dressing is changed, and at least every three days for optimal results. Studies report that using Granulox results in shorter healing time, reduced pain scores and total cost savings for healthcare providers compared to standard of care. Twice as many chronic wounds healed at 8–16 weeks compared to standard of care. Time to heal diabetic foot ulcers 50% shorter than with standard of care. Treatment costs in diabetic foot ulcers at least 40% lower than with standard of care. 99% less slough in chronic wounds after 4 weeks compared to 33% with standard of care.

Precautions

Do not use Granulox on patients and/or user with known hypersensitivity to the product materials components. Some wound antiseptics are known to impair the efficacy of Granulox. Therefore, after application of an antiseptic, the wound area must be flushed thoroughly with the physiological solution. Do not use with occlusive plastic films and hydrocolloids. Hypersensitivity reactions to any of the ingredients may occur. If your symptoms worsen or you develop side effects, stop using Granulox and consult a doctor.

Warnings

Granulox should not be used on pregnant women. Granulox should not be used simultaneously with locally acting medicines, such as antibiotics, because no data on potential interactions with Haemoglobin is available.